AVITA Medical Names Robin VanDenburgh as SVP of U.S. Commercial Sales
August 01 2024 - 3:05PM
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage
regenerative medicine company focused on first-in-class devices for
wound care management and skin restoration, is pleased to announce
that industry leader Robin VanDenburgh has joined as Senior Vice
President of U.S. Commercial Sales, effective August 6, 2024.
VanDenburgh, who most recently served as Vice President of Key
Accounts at Smith & Nephew (NYSE: SNN), will spearhead AVITA
Medical’s efforts to expand its market presence and drive sales
growth in the U.S.
“Robin brings a wealth of experience in leading and developing
high-performing sales teams,” said Jim Corbett, Chief Executive
Officer of AVITA Medical. “Her proven ability to drive new product
adoption and growth across multiple specialties makes her the ideal
leader to expand the treatment capabilities of RECELL GO and
advance our innovative portfolio of wound care solutions. We are
confident that her strategic vision and industry expertise will be
instrumental in driving our U.S. commercial success and
accelerating growth.”
VanDenburgh is an accomplished executive with more than 25 years
of experience building sales teams and driving revenue growth in
the healthcare industry. During her 12-year tenure at Smith &
Nephew, she held senior-level sales management positions of
increasing responsibility with cross-functional responsibility
within their advanced wound division, which included medical
devices, biologics, and dressings. Prior to that, she held a sales
management position at Aureon Biosciences, where she managed and
developed a new sales team, 60% of whom were her direct hires. She
also held regional and divisional management roles at St. Jude
Medical and Ethicon Endo-Surgery, a Johnson & Johnson
company.
About AVITA Medical, Inc.AVITA Medical® is a
commercial-stage regenerative medicine company transforming the
standard of care in wound care management and skin restoration with
innovative devices. At the forefront of our platform is the RECELL®
System, approved by the U.S. Food and Drug Administration for the
treatment of thermal burn wounds and full-thickness skin defects,
and for repigmentation of stable depigmented vitiligo lesions.
RECELL harnesses the regenerative properties of a patient’s own
skin to create Spray-On Skin™ Cells, delivering a transformative
solution at the point-of-care. This breakthrough technology serves
as the catalyst for a new treatment paradigm enabling improved
clinical outcomes. AVITA Medical also holds the exclusive rights to
market, sell, and distribute PermeaDerm®, a biosynthetic wound
matrix, in the United States.
In international markets, the RECELL System is approved to
promote skin healing in a wide range of applications including
burns, full-thickness skin defects, and vitiligo. The RECELL System
is TGA-registered in Australia, has received CE-mark approval in
Europe, and has PMDA approval in Japan.
To learn more, visit www.avitamedical.com.
Forward-Looking Statements This press release
may contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such
forward-looking statements are subject to significant risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied by such statements. Forward-looking
statements generally may be identified by the use of words such as
“anticipate,” “expect,” “intend,” “could,” “may,” “will,”
“believe,” “estimate,” “look forward,” “forecast,” “goal,”
“target,” “project,” “continue,” “outlook,” “guidance,” “future,”
and similar words or expressions, and the use of future dates.
Forward-looking statements include, but are not limited to,
statements concerning the potential for future growth of our
business and our ability to achieve financial goals. These
statements are made as of the date of this release, and the Company
undertakes no obligation to publicly update or revise any of these
statements, except as required by law. For additional information
and other important factors that may cause actual results to differ
materially from forward-looking statements, please see the “Risk
Factors” section of the Company’s latest Annual Report on Form 10-K
and other publicly available filings for a discussion of these and
other risks and uncertainties.
Authorized for release by the Chief Financial Officer of AVITA
Medical, Inc.
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/657160c0-7585-4093-8b52-fb05f8da004f
Investor & Media Contact:
Jessica Ekeberg
Phone +1-661-904-9269
investor@avitamedical.com
media@avitamedical.com
Avita Medical (NASDAQ:RCEL)
Historical Stock Chart
From Jul 2024 to Aug 2024
Avita Medical (NASDAQ:RCEL)
Historical Stock Chart
From Aug 2023 to Aug 2024